Fractionated SRT using VMAT and Gamma Knife for brain metastases and gliomas--a planning study

Stereotactic and fractionated stereotactic radiosurgery for single and multiple brain metastases: Results of multicenter planning studies

PURPOSE

Stereotactic and fractionated stereotactic radiosurgery (SRS/fSRS) utilization is growing in India, although planning studies are scarce. This study assessed clinical practices for SRS/fSRS treatment planning for brain metastases (BM) using ICRU-91 and explored the impact of planning tools.

METHODS & MATERIALS

Participants from 23 centers received two anonymized CT datasets with predrawn structures for single met (SM) and four BMs (MM) cases via email. Centers used local protocol to create plans. The plans were evaluated for target coverage, normal brain doses, and ICRU-91 dosimetric indices.

RESULTS

Monaco TPS overestimated mean GTV (PTV) by 3.7 (4.2)% and 2.1 (2.0)% for SM and MM respectively. Some institutions had good conformity and target coverage, whereas others had high OAR doses despite inadequate PTV dose coverage. Conformity index (CI) ranged from 1.07 to 1.45 (SM) and 1.06 to 1.25 (MM), and homogeneity index (HI) ranged from 0.07 to 0.28 (SM) and 0.13 to 0.32 (MM). Significant variation in GI and dose prescription isodose line selection was observed among centers.

CONCLUSIONS

There was a significant heterogeneity in the planning parameters noted among different centers. The study emphasized the importance of established planning protocols and comprehensive training for staff involved in SRS/fSRS. Notably, plans with finer MLC width outperformed, yet wider MLC plans achieved ICRU-91 indices comparable to published literature. The importance of our study is underscored by the absence of a national framework for SRS planning in India.

Assessment of automated non-coplanar stereotactic radiosurgery planning in single isocenteric linac-based treatment for brain metastases with respect to planner's experience

One of the reasons for planning heterogeneity is lack of enough experience and recommendations on the quality of Linac-based stereotactic radiosurgery (SRS). In this study, our goal is to investigate the impact of planner's experience on the quality of Linac-based SRS plans for brain metastases (BMs) with varying levels of complexity. Specifically, to assess the impact of experience on the outcome of an automated noncoplanar treatment planning. A cohort of 120 patients with intracranial SRS plans, with a total of 633 BMs, was examined using VMAT delivery calculated with an available automated plan delivery system. Four planners with different levels of experience, ranging from under 1 year to over 5 years (Expert planner) of SRS planning, generated treatment plans. Dosimetric parameters and plan quality metrics were evaluated including: conformality index, homogeneity index, modulation factor, R50%, total volume of brain receiving 12Gy, 6Gy, and 3Gy (V12Gy, V6Gy, V3Gy) were assessed for each plan and compared with plan which was created by an expert planner with the highest planning experience. Experienced planners consistently produced acceptable plans, while less experienced one required revisions. Single BM cases showed minimal deviations in dosimetric parameters (under 10%) irrespective of planner experience. However, as the number and complexity of BMs increased, differences in plan quality became more pronounced. Moreover, expert planner's plans consistently outperformed others in terms of organs at risk sparing. This difference was particularly pronounced for cases involving the volume of healthy brain tissue. Our study underscores the critical role of planner's experience in the quality of Linac-based SRS plans using an automated planning. By standardizing and enhancing the planning process, the study aims to improve the quality of care for patients with multiple BMs, contributing to more efficient and effective treatments in the field of SRS.

Innovations in intraoperative therapies in neurosurgical oncology: a narrative review

PURPOSE

High-grade gliomas (HGG) represent the most aggressive primary brain tumors in adults, characterized by high recurrence rates due to incomplete resection. This review explores the effectiveness of emerging intraoperative therapies that may extend survival by targeting residual tumor cells. The main research question addressed is: What recent intraoperative techniques show promise for complementing surgical resection in HGG treatment?

METHODS

A comprehensive literature review was conducted, examining recent studies on intraoperative therapeutic modalities that support surgical resection of HGG. Techniques reviewed include laser interstitial thermal therapy (LITT), intraoperative brachytherapy, photodynamic therapy (PDT), sonodynamic therapy (SDT), and focused ultrasound (FUS). Each modality was evaluated based on clinical application, evidence of effectiveness, and potential for integration into standard HGG treatment protocols.

RESULTS

Findings indicate that these therapies offer distinct mechanisms to target residual tumor cells: LITT provides localized thermal ablation; intraoperative brachytherapy delivers sustained radiation; PDT and SDT activate cytotoxic agents in tumor cells; and FUS enables precise energy delivery. Each method has shown varying levels of clinical success, with PDT and LITT currently more widely implemented, while SDT and FUS are promising but under investigation.

CONCLUSION

Intraoperative therapies hold potential to improve surgical outcomes for HGG by reducing residual tumor burden. While further clinical studies are needed to optimize these techniques, early evidence supports their potential to enhance the effectiveness of surgical resection and improve patient survival in HGG management.

Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy

BACKGROUND

The role of Gamma Knife radiosurgery (GKRS) in recurrent glioblastoma remains unclear. The purpose of this study is to evaluate the effects of GKRS in a group of patients with recurrent glioblastoma, focusing on survival and safety.

METHODS

Patients undergoing GKRS for recurrent glioblastoma between September 2014 and April 2019 were included in this study. Relevant clinical and radiosurgical data, including GKRS-related complications, were recorded and analyzed. Overall survival (OS), local progression free survival (LPFS) and prognostic factors for outcome were thoroughly evaluated.

RESULTS

Fifty-three patients were analyzed (24 female, 29 male). The median age was 50 years (range, 19-78 years). The median GKRS treatment volume was 35.01 cm3 (range, 2.38-115.57 cm3). Twenty patients (38%) were treated with single fraction GKRS, while 33 (62%) were treated with GKRS-based hypofractionated stereotactic radiotherapy (HSRT). The median prescription dose for single fraction GKRS, 3-fractions HSRT and 5-fractions HSRT were 16 Gy (range, 10-20 Gy), 27 Gy (range, 18-33 Gy) and 25 Gy (range, 25-30 Gy), respectively. The median LPFS and OS times were 8.1 months and 11.4 months after GKRS, respectively. HSRT and Bevacizumab were associated with improved LPFS, while HSRT alone was associated with longer OS.

CONCLUSION

Our findings suggested that HRST would likely improve LPFS and OS in definite settings; the addition of Bevacizumab to GKRS was associated with increased rates of local control. No major complications were reported. Further prospective studies are warranted to confirm our findings.

Improving on whole-brain radiotherapy in patients with large brain metastases: A planning study to support the AROMA clinical trial

PURPOSE

To develop a novel dose-escalated volumetric modulated arc therapy (VMAT) strategy for patients with single or multiple large brain metastases which can deliver a higher dose to individual lesions for better local control (LC), and to compare dosimetry between whole brain radiotherapy (WBRT), hippocampal-sparing whole brain radiotherapy (HS-WBRT) and different VMAT-based focal radiotherapy approaches.

METHODS AND MATERIALS

We identified 20 patients with one to ten brain metastases and at least one lesion larger than 15 cm³ who had received WBRT as part of routine care. For each patient, we designed and evaluated five radiotherapy treatment plans, including WBRT, HS-WBRT and three VMAT dosing models. A dose of 20 Gy in 5 fractions was prescribed to the whole brain or target volumes depending on the plan, with higher doses to smaller lesions and dose-escalated inner planning target volumes (DE-iPTV) in VMAT plans, respectively. Treatment plans were evaluated using the efficiency index, mean dose and D0.1cc to the target volumes and organs at risk.

RESULTS

Compared with WBRT, VMAT plans achieved a significantly more efficient dose distribution in brain lesions, especially with our DE-iPTV model, while minimising the dose to the normal brain and other organs at risks (OARs) (p < 0.05).

CONCLUSIONS

VMAT plans obtained higher doses to brain metastases and minimised doses to OARs. Dose-escalated VMAT for larger lesions allows higher radiotherapy doses to be delivered to larger lesions while maintaining safe doses to OARs.

Cerebral metastases

Brain metastases are common and deadly. Over the last 25 years GKNS has been established as an invaluable treatment. It may be used as a primary treatment or after either surgery or WBRT. Patients are assessed using one of a number of available scales. GKNS may be repeated for new metastases and for unresponsive tumors. Prescription doses are usually between 18 and 20Gy. The use of advanced MR techniques to highlight sensitive structures like the hippocampi have extended the efficacy of the treatment. More recently GKNS has been used with different target therapies with improved results. More recently frameless treatments have become more popular in this group of very sick patients. GKNS controls tumors in between 80% and over 95% of cases and may even be used for brainstem tumors.

Pituitary adenoma treatment plan quality comparison between linear accelerator volumetric modulated arc therapy and Leksell Gamma Knife® radiosurgery

The aim of this study was to compare radiosurgical treatment plan quality of a linear accelerator with Leksell Gamma Knife (LGK) for pituitary adenoma irradiation. Thirty pituitary adenoma patients were evaluated in this study. Treatment plans were prepared on LGK and stereotactic linear accelerator Varian TrueBeam STx. Volumetric Modulated Arc Therapy (VMAT) plans (21 plans with 2 coplanar arcs and 9 plans with 4 non-coplanar arcs) were calculated for linear accelerator. All the plans were evaluated in terms of conformity, selectivity, gradient index and organ at risk (OAR) sparing. VMAT produced dosimetrically comparable treatment plans to LGK regarding conformity and selectivity (New Conformity Index (NCI): 1.76 ± 0.65 for 4 arc VMAT, 2.33 ± 1,16 for 2 arc VMAT and 1.96 ± 0.71 for LGK; Selectivity Index (SI): 0.63 ± 0.16 for 4 arc VMAT, 0.51 ± 0.16 for 2 arc VMAT and 0.58 ± 0.17 for LGK). Gradient index (GI) was superior for LGK plans (GI: 2.74 ± 0.20 for LGK and 5.28 ± 2.29 for 4 arc VMAT). OAR sparing for optics, brainstem, and hypophysis was similar for both modalities while target volume coverage was maintained the same. Finally, treatment time resulted in favor of VMAT plans (in this study VMAT plans were almost 5 times faster than LGK treatment regarding beam on time). According to the results of this study stereotactic linear accelerator with VMAT treatment could be used as a reasonable alternative to LGK for pituitary adenoma radiosurgery but only if the same head fixation method accuracy and target volume delineation are maintained for both modalities.

Transition From Manual to Automated Planning and Delivery of Volumetric Modulated Arc Therapy Stereotactic Radiosurgery: Clinical, Dosimetric, and Quality Assurance Results

PURPOSE

Properly planned single isocenter volumetric modulated arc therapy (VMAT) radiosurgery plans exhibit high quality and efficiency. We report here the largest clinical experience to date, to our knowledge, comparing manual planning with a new automated platform designed to standardize and simplify radiosurgery planning and delivery processes.

METHODS

We treated 693 patients with single isocenter VMAT radiosurgical plans generated by either our conventional manual (mVMAT) or a recently implemented automated (HyperArc^TM) technique. All plans targeted the gross tumor volume without margin. Radiochromic film was used for patient-specific quality assurance (PSQA). We evaluated local control and toxicity data for a subgroup of 107 patients having 377 metastatic tumors that were treated with HyperArc.

RESULTS

The median Radiation Therapy Oncology Group (RTOG) conformity index was 1.14 and was not different between the 2 techniques. The median Paddick gradient index was 5.42 for HyperArc versus 7.09 for mVMAT (P < .001). The median mean brain doses were 4.6% and 5.1% for HyperArc and mVMAT, respectively (P = .04). The PSQA for both techniques met clinical criteria, but 97% of the HyperArc plans satisfied the gamma tolerance limit recommended by the American Association of Physicists in Medicine Task Group No. 218, compared with 94% of the mVMAT plans (P = .02). The median treatment-planning times were not significantly different. The median treatment times were 10.5 and 11.4 minutes for HyperArc and mVMAT, respectively (P < .001). The Kaplan-Meier estimate of local control was 90.1% at 1 year.

CONCLUSIONS

HyperArc produces high-quality radiosurgical plans that are at least as good as mVMAT plans created by an expert manual planner with easier planning and more efficient delivery workflow. A less experienced planner can produce very high-quality radiosurgical plans even for patients with more than 10 targets. The use of a single-isocenter technique for multiple targets with no PTV margin did not compromise clinical outcomes, and 1-year local control for treated targets remained congruent with historical series.

Dosimetric comparison of Gamma Knife® IconTM and linear accelerator-based fractionated stereotactic radiotherapy (FSRT) plans for the re-irradiation of large (>14 cm3) recurrent glioblastomas

Our objective is to investigate dosimetric differences between clinically deliverable Gamma Knife^® (GK) Icon™ and linac-based FSRT plans on the basis of normal brain dose sparing for large (>14 cm³) recurrent glioblastomas (GBM). Sixteen patients with large, recurrent GBM were treated using re-irradiation via linac-based FSRT, 35 Gy in 10 fractions. For each patient, a new GK FSRT plan was created in Leksell GammaPlan^® V11 (LGP). To maintain clinical deliverability, the LGP optimization included a planning goal of treatment time <20 minutes per fraction. Dosimetric comparison of coverage and normal brain dose between the linac and GK treatment plans was performed in MIM. The GK FSRT plans had significantly (p < 0.05) lower mean normal brain dose values (-8.85%), mean values of normal brain V20 (-32.4%) and V12 (-25.9%), and a lower mean V4 (-10.0%). GK FSRT plans have the potential to reduce the risk of radiation-related toxicities.

Is there a volume threshold of brain metastases for Linac-based stereotactic radiotherapy?

PURPOSE

To investigate whether there is a volume threshold in target volume of brain metastases below which a small cone size and sharp penumbra in Gamma Knife (GK) may provide improved plan quality when compared to Volumetric Modulated Arc Therapy (VMAT)-based stereotactic radiosurgery (SRS).

METHODS

For patients treated on GK SRS for brain metastases in 2018-2019 in our institution, 121 patients with two and three targets were identified. Twenty-six patients with two or three brain metastases (total of 76 lesions) were selected for this study. Two VMAT plans, SmartArc (Pinnacle) and HyperArc (Eclipse), were generated retrospectively for each patient. Plan quality was evaluated based on RTOG conformity index (CI), Paddick gradient index (GI), normal tissue (NT) V12Gy and V4.5Gy. By using the receiver operating characteristic (ROC) curve for both VMAT plans (SmartArc and HyperArc) and metrics of RTOG CI and NT V12Gy, we compared GK plans to SmartArc and HyperArc plans separately to determine the threshold volume.

RESULTS

For SmartArc plans, both ROC curve analyses showed a threshold volume of 0.4 cc for both CI and NT V12Gy. For HyperArc plans, the threshold volumes were 0.2 cc for the CI and 0.5 cc for NT V12Gy. GK plans produced improved dose distribution compared to VMAT for targets ≤0.4 cc, but HyperArc was found to have competing results with GK in terms of CI and NT V12Gy. For targets > 0.4 cc, both SmartArc and HyperArc showed better plan quality when compared to the GK plans.

CONCLUSIONS

Target volumes ≤0.4 cc may require a small cone size and sharp penumbra in GK while for target volumes >0.4 cc, VMAT-based SRS can provide improved overall plan quality and faster treatment delivery.

Stereotactic radiotherapy of appropriately selected meningiomas and metastatic brain tumor beds with gamma knife icon versus volumetric modulated arc therapy

PURPOSE

To determine if the gamma knife icon (GKI) can provide superior stereotactic radiotherapy (SRT) dose distributions for appropriately selected meningioma and post-resection brain tumor bed treatments to volumetric modulated arc therapy (VMAT).

MATERIALS AND METHODS

Appropriately selected targets were not proximal to great vessels, did not have sensitive soft tissue including organs-at-risk (OARs) within the planning target volume (PTV), and did not have concave tumors containing excessive normal brain tissue. Four of fourteen candidate meningioma patients and six of six candidate patients with brain tumor cavities were considered for this treatment planning comparison study. PTVs were generated for GKI and VMAT by adding 1 mm and 3 mm margins, respectively, to the GTVs. Identical PTV V_100% -values were obtained for the GKI and VMAT plans for each patient. Meningioma and tumor bed prescription doses were 52.7-54.0 in 1.7-1.8 Gy fractions and 25 Gy in 5 Gy fractions, respectively. GKI dose rate was 3.735 Gy/min for 16 mm collimators.

RESULTS

PTV radical dose homogeneity index was 3.03 ± 0.35 for GKI and 1.27 ± 0.19 for VMAT. Normal brain D_1% , D_5% , and D_10% were lower for GKI than VMAT by 45.8 ± 10.9%, 38.9 ± 11.5%, and 35.4 ± 16.5% respectively. All OARs considered received lower maximum doses for GKI than VMAT. GKI and VMAT treatment times for meningioma plans were 12.1 ± 4.13 min and 6.2 ± 0.32 min, respectively, and, for tumor cavities, were 18.1 ± 5.1 min and 11.0 ± 0.56 min, respectively.

CONCLUSIONS

Appropriately selected meningioma and brain tumor bed patients may benefit from GKI-based SRT due to the decreased normal brain and OAR doses relative to VMAT enabled by smaller margins. Care must be taken in meningioma patient selection for SRT with the GKI, even if they are clinically appropriate for VMAT.

Selection of prescription isodose line for brain metastases treated with volumetric modulated arc radiotherapy

Purpose

To exploit the optimal prescription isodose line (IDL) for brain metastases treated with volumetric modulated arc radiotherapy (VMAT) as there is no consensus on the selection of IDL with VMAT.

Methods and materials

Eighteen patients with 20 brain tumors, who were treated with VMAT, were enrolled in this study. For each tumor of every patient, five plans were designed with IDL ranging from 50% to 90% in 10% increments. Different IDLs were obtained through adjusting the constraint parameters during planning optimization. Prescription dose (10 × 5 Gy) were identical for all plans, and the plans were compared in terms of gradient index (GI), conformity Index (CI), V26 Gy/V_PTV, and V32 Gy/V_PTV in normal brain tissue, which correlate to radiation necrosis.

Results

IDL with lowest GI has a median value of 60.0% (ranging from 50% to 80%). Except for one tumor with volume larger than 10 cc, the IDL with lowest GI varies from 50% to 70%, which depends on the shape of PTV, location, and whether the target volume is adjacent to crucial OAR. Moreover, there is no significant difference for CI with varying IDL plans. The average V26 Gy/V_PTV and V32 Gy/V_PTV in normal brain tissue 60% IDL plans are 27.3%, 31.7% lower than 90% IDL plans separately (P < 0.05). However, by further decreasing IDL from 60% to 50%, the average V26 Gy/V_PTV and V32 Gy/V_PTV may increase comparing with 60% IDL plans (P > 0.05). Furthermore, a lower IDL is found to result in higher mean dose to the target volume (P < 0.05).

Conclusions

Plans using VMAT with PTV smaller than 10 cc tend to be optimal with IDL around 60–70% for lower GI, smaller V26 Gy/V_PTV, V32 Gy/V_PTV in normal brain tissue, and higher mean dose in tumor comparing with high IDL plans which have potential benefit in reducing risk of radiation necrosis and increasing the local control. However, IDL lower than 60% is not recommended for the disadvantage of increasing V26 Gy/V_PTV and V32 Gy/V_PTV in normal brain tissue.

Dosimetric quality and delivery efficiency of robotic radiosurgery for brain metastases: Comparison with C-arm linear accelerator based plans

The incidence of brain metastases is increasing and various treatment modalities exist for brain metastases. The aim of this study was to investigate the dosimetric quality and delivery efficiency of robotic radiosurgery (CyberKnife) for multiple brain metastases compared with C‐arm linear accelerator (linac) based plans. C‐arm linac based plans included intensity‐modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) and non‐coplanar VMAT with 1, 3 and 5 non‐coplanar arcs, respectively (NC1, NC3 and NC5). For 20 patients, six plans with a prescription dose of 30 Gy in three fractions were generated. The gradient index (GI), conformity index (CI), maximum dose (D_max) of organs at risk (OARs), normal brain tissue volume (V_3 Gy–V_24 Gy), monitor units (MUs) and beam on time (BT) were evaluated. The GI of CyberKnife plans (3.60 ± 0.70) was lower than IMRT (6.21 ± 2.26, P < 0.05), VMAT (6.04 ± 1.93, P < 0.05), NC1 (5.16 ± 1.71, P < 0.05), NC3 (5.02 ± 1.59, P < 0.05) and NC5 (5.03 ± 1.72, P < 0.05). The CI of the VMAT plans (both coplanar and non‐coplanar) was larger than IMRT and CK plans. The D_max for most OARs of the CyberKnife plan was lower than the C‐arm linac based plans, although some differences were not statistically significant. The normal brain tissue volume of CyberKnife plan was lower than the C‐arm linac based plans, and the normal brain tissue volume of non‐coplanar VMAT plans was lower than IMRT and VMAT plans at high‐moderate dose level. However, the MUs and BT of CyberKnife plans was more than C‐arm linac based plans. CyberKnife plan was better than C‐arm linac based plans in protecting normal brain tissue and OARs for patients with multiple brain metastases. C‐arm linac based plan with non‐coplanar arc provided better protection of normal brain tissue than coplanar plan. However, the BT of CyberKnife plan was longer than C‐arm linac based plans.

Individualized automated planning for dose bath reduction in robotic radiosurgery for benign tumors

Object

To explore the use of automated planning in robotic radiosurgery of benign vestibular schwannoma (VS) tumors for dose reduction outside the planning target volume (PTV) to potentially reduce risk of secondary tumor induction.

Methods

A system for automated planning (AUTOplans) for VS patients was set up. The goal of AUTO- planning was to reduce the dose bath, including the occurrence of high dose spikes leaking from the PTV into normal tissues, without worsening PTV coverage, OAR doses, or treatment time. For 20 VS patients treated with 1x12 Gy, the AUTOplan was compared with the plan generated with conventional, manual trial-and-error planning (MANplan).

Results

With equal PTV coverage, AUTOplans showed clinically negligible differences with MANplans in OAR sparing (largest mean difference for all OARs: ΔD2% = 0.2 Gy). AUTOplan dose distributions were more compact: mean/maximum reductions of 23.6/53.8% and 9.6/28.5% in patient volumes receiving more than 1 or 6 Gy, respectively (p<0.001). AUTOplans also showed smaller dose spikes with mean/maximum reductions of 22.8/37.2% and 14.2/40.4% in D2% for shells at 1 and 7 cm distance from the PTV, respectively (p<0.001).

Conclusion

Automated planning for benign VS tumors highly outperformed manual planning with respect to the dose bath outside the PTV, without deteriorating PTV coverage or OAR sparing, or significantly increasing treatment time.

Tailored Treatment Options for Patients with Brain Metastases by a Relocatable Frame System with Gamma Knife Radiosurgery

OBJECTIVE

To report on our experience with the Elekta Extend system, a relocatable frame system used in patients with brain metastases for single-session, hypofractionated, or staged hypofractionated Gamma Knife radiosurgery (GKRS); and the evaluation of its efficacy.

METHODS

From March 2014 to September 2016, 856 patients with brain metastases underwent GKRS at our hospital. Of them, 35 patients who were retrospectively investigated, were selected for treatment with GKRS using the relocatable frame system. Individualized treatment strategy was chosen according to prior treatment history, number, size and location of tumor, or tumor harboring gene mutation.

RESULTS

Thirty-two (91.4%) patients underwent treatment with hypofractionated GKRS or staged hypofractionated GKRS, whereas 3 (8.6%) patients underwent single session GKRS. The mean radial setup difference from the reference measurements was 0.50 ± 0.16 mm. The median follow-up time after GKRS with the Extend system was 12 months (range, 1-45 months). The median overall survival time was 12 months (95% confidence interval 6.43-17.57). On multivariable analysis, performance status and extracranial metastases were independently prognostic factors for overall survival. Radiation necrosis developed in 4 cases (11.4%) during the follow-up period (2 with common terminology criteria for adverse events grade 2 and 2 with its grade 3).

CONCLUSIONS

The relocatable frame system can maintain submillimetric accuracy and provide tailored treatment option with reasonable tumor control and good survival benefits in selected patients with brain metastases. Especially, hypofractionated GKRS or staged hypofractionated GKRS with noninvasive frame is a safe and effective treatment option for large brain metastases or tumor adjacent to eloquent structures.

Gamma Knife and volumetric modulated arc therapy stereotactic radiosurgery plan quality and OAR sparing comparison for pituitary adenomas and vestibular schwannomas

PURPOSE

To compare the plan quality and organs at risk (OAR) sparing of auto-planned volumetric modulated art therapy (VMAT) and Gamma Knife (GK) for stereotactic radiosurgery of pituitary adenomas (PA) and vestibular schwannomas (VS).

METHODS

VMAT radiosurgery plans were made using auto planning tool for eight vestibular schwannoma and eight pituitary adenoma patients previously treated with GK. VMAT plans were made with three non-coplanar arcs using 315, 0 and 45 degrees angles, 6MV FFF energy at 1400 MU/min dose rate and 2.5 mm thick MLC leaves. Both GK and VMAT plans were prescribed to similar isodose lines (50% - 60%).

RESULTS

Respectively for GK and VMAT, the mean Paddick conformity index (PCI) was 0.62 ± 0.08 and 0.67 ± 0.10 (p > 0.05) for PA and 0.72 ± 0.09 and 0.660 ± 0.13 (p > 0.05) for VS; the mean gradient index (GI) was 2.76 ± 0.14 and 3.14 ± 0.40 Gy (p < 0.05) for PA and 3.71 ± 1.83 and 3.60 ± 0.84 Gy (p > 0.05) for VS; mean brainstem maximum dose was 9.13 ± 3.50 Gy and 7.31 ± 2.01 Gy (p > 0.05) for PA and 11.67 ± 4.56 Gy and 12.22 ± 4.55 Gy (p > 0.05) for VS; mean optic nerve maximum dose was 9.66 ± 1.0 Gy and 7.67 ± 2.58 Gy (p < 0.05); mean cochlea mean dose was 7.31 ± 2.7 Gy and 7.23 ± 3.13 Gy (p > 0.05); and mean treatment time was 68 min and 5 min for PA and 40 min and 3 min for VS.

CONCLUSIONS

Auto planning with standard template simplified the planning stage for VMAT and provided clinically acceptable plans. Comparison of GK and VMAT for plan quality and OAR sparing varied across patients but both were overall comparable.

Stereotactic radiosurgery for multiple brain metastases: Results of multicenter benchmark planning studies

PURPOSE

Stereotactic radiosurgery is indicated for treatment of multiple brain metastases. Various treatment platforms are available, but most comparisons are limited to single-center studies. As part of a national commissioning program, benchmark planning cases were completed by 21 clinical centers, providing a unique dataset of current practice across a large number of providers and equipment platforms.

METHODS AND MATERIALS

Two brain metastases cases were provided, with images and structures predrawn, involving 3 and 7 lesions. Centers produced plans according to their local practice, which were reviewed centrally using metrics for target coverage, selectivity, gradient fall-off, and normal tissue sparing.

RESULTS

Fifty plans were submitted, using 24 treatment platforms. Eleven plans were revised following feedback, including 2 centers that acquired a new platform; 1 other center accepted a restriction of service. All centers prioritized coverage, with the prescription isodose covering ≥95% of 233 of 235 target volumes. Selectivity was much more variable, especially for smaller lesions, and when combined with poor gradient indices resulted in large volumes of normal tissue being irradiated. Tomotherapy submissions were outliers for either selectivity or gradient index, but other platforms could produce plans with relatively low gradient indices for larger lesion volumes. There was more variation among Varian and Elekta LINAC plans than for Gamma Knife and CyberKnife, and larger differences for smaller targets, both inter- and intratreatment platform. Doses to normal brain and brainstem were highest when margins were applied, but improvements were possible by replanning alone.

CONCLUSIONS

Multicenter benchmarking exercises have highlighted some variation in clinical practice and priorities, with a few outliers. Most platforms are able to achieve comparable plans, except for the smallest volumes and when larger planning margins are used. The data will be used to advance standardization and quality improvement of national services and can provide useful guidance for centers worldwide.

Plan Quality and Treatment Efficiency for Radiosurgery to Multiple Brain Metastases: Non-Coplanar RapidArc vs. Gamma Knife

Objectives

This study compares the dosimetry and efficiency of two modern radiosurgery [stereotactic radiosurgery (SRS)] modalities for multiple brain metastases [Gamma Knife (GK) and LINAC-based RapidArc/volumetric modulated arc therapy], with a special focus on the comparison of low-dose spread.

Methods

Six patients with three or four small brain metastases were used in this study. The size of targets varied from 0.1 to 10.5 cc. SRS doses were prescribed according to the size of lesions. SRS plans were made using both Gamma Knife^® Perfexion and a single-isocenter, multiple non-coplanar RapidArc^®. Dosimetric parameters analyzed included RTOG conformity index (CI), gradient index (GI), 12 Gy isodose volume (V_12Gy) for each target, and the dose “spread” (Dspread) for each plan. Dspread reflects SRS plan’s capability of confining radiation to within the local vicinity of the lesion and to not spread out to the surrounding normal brain tissues. Each plan has a dose (Dspread), such that once dose decreases below Dspread (on total tissue dose–volume histogram), isodose volume starts increasing dramatically. Dspread is defined as that dose when volume increase first exceeds 20 cc/0.1 Gy dose decrease.

Results

RapidArc SRS has smaller CI (1.19 ± 0.14 vs. 1.50 ± 0.16, p < 0.001) and larger GI (4.77 ± 1.49 vs. 3.65 ± 0.98, p < 0.01). V_12Gy results were comparable (2.73 ± 1.38 vs. 3.06 ± 2.20 cc, p = 0.58). Moderate to lower dose spread, V6, V4.5, and V3, were also equivalent. GK plans achieved better very low-dose spread (≤3 Gy) and also had slightly smaller Dspread, 1.9 vs. 2.5 Gy. Total treatment time for GK is estimated between 60 and 100 min. GK treatments are between 3 and 5 times longer compared to RapidArc treatment techniques.

Conclusion

Dosimetric parameters reflecting prescription dose conformality (CI), dose fall off (GI), radiation necrosis indicator (V_12Gy), and dose spread (Dspread) were compared between GK SRS and RapidArc SRS for multi-mets. RapidArc plans have smaller CI but larger GI. V_12Gy are comparable. GK appears better at reducing only very low-dose spread (<3 Gy). The treatment time of RapidArc SRS is significantly reduced compared to GK SRS.